The Coalition for Epidemic Preparedness Innovations (CEPI) granted funding to Inovio Pharmaceuticals and Moderna for the development of a vaccine against the new coronavirus that emerged in China last month.
So far, the virus has killed nearly 25 people and infected 830 individuals.
Inovio will use the CEPI grant to carry out preclinical and clinical development through Phase I human testing of its vaccine candidate, INO-4800, matched to the new coronavirus strain.
The company will work with Wistar Institute, GeneOne Life Science unit VGXI and Twist Bioscience to develop the vaccine.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Moderna intends to develop a messenger RNA (mRNA) vaccine for the virus. The company will use the CEPI funding to manufacture the vaccine.
To design the vaccine, Moderna partnered with the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
NIAID will perform investigational new drug (IND)-enabling studies and a Phase I clinical trial in the US.